Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

With such a long horizon, why buy shares now when, given the small volume and long runway, it is the future that portends true, financial success for committed shareholders? I would not characterize a firm with a five year horizon as an explosive powder keg. Does that not suggest cognitive dissonance?

Your question was about if/when I personally foresaw any serious buyout possibilities, so my answer was tailored to that specific parameter asked k! So with that in mind and given your response above...allow me to give an answer on my own personal growth expectations over the course of these next 5 years in quick point form:

1. Rexista NDA partnership and FDA approval should add a minimum quarter billion dollars in revenues per annum...and that approval could/should arrive within approximately 18 months(EOY 2016 IMO)

2. Profitability could/should be attained as soon as the FDA hands down imminent approval on both the 5mg and 10mg FocalinXR strengths that are both pending on the immediate horizon...followed by 20mg FocalinXR approval by end of this year

3. Protonix ANDA(already 57 months in the FDA's backlog of pending ANDA approvals) should be FDA approved and then licensing/partnership announced anytime now over the course of the next 12 months

4. Glucophage ANDA(already 57 months in the FDA's backlog of pending ANDA approvals) should be FDA approved and then licensing/partnership announced anytime now over the course of the next 12 months

5. Regabatin NDA should be submitted to the FDA within the next 12 to 18 months

6. 5 more ANDA's all already submitted to the FDA all of which have timelines waiting for FDA approval between 36 and 49 months...so all 5 will be approved well b4 the next 5 years runs its course

7. Coreg and several other pending ANDA's will be filed with the FDA over the course of the next 5 years

8. IPCI has already stated that following Rexista and Regabatin NDA's that their game changing tech platform can be applied to all narcotics...so logic would suggest that if/when they receive a best-in-class designtation on Rexista...there's a strong possibility IPCI will be filing other opioid based NDA's with the FDA

9. IPCI recently announced a large expansion in their manufacturing capabilities with the pending property purchase PR which opens the door wide open for other opioid biotech firms to start coming to IPCI at some point over the course of the next 5 years to get IPCI to manufacture opioid's for them incorporating IPCI's proprietary delivery tech platform

10. As all of the above catalysts/valuation driving developments/results get unleashed...obviously the perceived let alone projected value of IPCI's share price currently, 18 months from now and especially over the entire course of the next 5 years will increase exponentially. So unless you don't view at least 2 more FDA ANDA approvals(within 12 months), a Rexista FDA NDA approval(within 18 months), and 3 more pending FocalinXR strengths approvals(this year) as near term tremendous valuation driving catalysts of powder keg proportions I can't help you...as the only cognitive dissonance that suggests is being incapable of just doing the available due on what could/should be delivered by way of growth driving catalysts here over just the next 18 months...let alone the next 5 years!

As to the CEOs perspective on a buyout and their focus for the future...you must realize that is what you want him to say. No CEO should say they were only making short term decisions designed to lead to a buyout. In fact, his statements indicating a long term view only serve to support a stronger negotiating position should a buyer come calling

No argument there...I want CEO Odidi to begin delivering all of IPCI's pending goods/proving their game changing proprietary tech platforms because I want to participate in an extraordinary growth curve here that provides life changing returns. Anyone who's followed Dr Odidi over the past few years knows how adamant he is about building/executing his life long dream here and delivering game changing value-driven results. So I totally concur with your thoughts that of course I totally agree with CEO Odidi's stance on any potential future buyouts

Finally, I will offer one thing more, an observation that a highly respected CEO once articulated that has always stuck with me..."I would rather be on time with good, than late with great."

And I will offer one final perspective myself...CEO Odidi' has 8 pending ANDA's 7 of which have all already been filed with the FDA for over 3 years awaiting FDA approval. He also has 4 more FocalinXR strengths all pending FDA approval. All of these ANDA's now completely outside of his/IPCI's control...solely in the hands of the FDA's ANDA backlog/timeline to approval.

CEO Odidi is also currently working on submitting Rexista bioequivalence by the end of this year prior to announcing a Rexista partner and an official Rexista submission to the FDA. The FDA's 2 recent decisions to fast track Rexista and advise IPCI to skip Rexista phase III trials entirely has obviously sped up the projected timeline to Rexista FDA approval...so for me anyways CEO Odidi is not only good...he's been great...and because all of IPCI's ANDA's are in the "hard to manufacture" category...despite the FDA's ANDA backlog...there's no risk/fear of those ANDA approvals being too late whatsoever. Nor is there any fear of Rexista approval being too late either...since Rexista has a real possibility of receiving a deserved best-in-class designation if the delivery tech platform does all it's claimed to do glty